News

Allergan acquired Chase for an upfront payment of $125 million (subject to certain adjustments) and additional potential regulatory and sales milestone payments related to Chase's lead compound, CPC-201,

Opdivo is now the first and only programmed death-1 (PD-1) inhibitor approved for a hematologic malignancy in the European Union (EU). It is the company’s second immuno-oncology agent

In July 2016, daratumumab was granted a Breakthrough Therapy Designation (BTD) in this patient population.  In August 2012, Genmab granted Janssen Biotech, Inc. an exclusive worldwide license to

The Swiss drugmaker exercised its right to buy Selexys following a successful phase II trial to evaluate the latter’s investigational drug SelG1 for reducing vaso-occlusive pain crises in

This study will evaluate pharmacokinetics, safety and tolerability of DITEST in the target patient group of males with hypogonadism (Clinical Trials ID NCT02966652). Diurnal CEO Martin Whitaker said: "The

APL is a rare type of blood cancer that can kill within hours or days if it is not treated.  About 1,500 to 2,000 people in Europe are

The OPTICORE coating technology comprises two trigger systems and an accelerator to allow targeted drug release in the large intestine to improve local and/or systemic drug bioavailability. The inner

Under the terms of the agreement, Celgene committed $9 million to PharmAkea to extend the collaboration for 9 months. PharmAkea announced the original 3-year collaboration with Celgene in October

The phase 2 trial, dubbed Evolve, involved 14 patients ages 40 to 80 years who were undergoing percutaneous transluminal renal angioplasty and stenting. The study's endpoints were a change in